Definition
Sarafotoxins (SRTXs) are a group of 21-residue cardiotoxic peptides from snake venom that induce coronary vasoconstriction, show high-affinity binding to rat atrial and brain membranes and activate the hydrolysis of phosphoinositides1.
Related Peptides
SRTXs amino acid sequence shows a high degree of homology with that of endothelin, a recently described 21-residue vasoconstrictor peptide found in porcine aortic endothelium. This is remarkable, since endothelin is a natural compound of the mammalian vascular system while sarafotoxins are highly toxic components of snake venom 1. The SRTXs and endothelins (ETs) spontaneously fold into a defined tertiary structure with specific pairing of four cysteines into two disulfide bonds. Their structures show an interesting topological similarity to the core of the metalloproteinase interaction sites of the tissue inhibitors of metalloproteinases 2.
Discovery
SRTXs constitute a family of vasoactive peptides that were initially isolated from the venom of Atractaspis engaddensis, and that are structurally and functionally related to ETs. The first report on the structural similarity between SRTXs and ETs was published by Takasaki et al., in 1988 3.
Structural Characteristics
Four SRTXs-SRTX-a, SRTX-b,SRTX-c, and SRTX-d (6)-have been characterized so far. The four cysteinyl residues in the ETs and in the SRTXs are interconnected by disulfide bridges between positions 1 and 15 and 3 and 11, forming an intramolecular loop structure. Another characteristic of these peptides is their conserved hydrophobic C-terminal tail. Early reports indicate that SRTX-b binds with high affinity to certain sites in rat atrium and brain and stimulates inositol phospholipid hydrolysis 4. Studies suggest that the very low activities of SRTc are caused mainly by the Lys9 to Glu9 substitution, but not by the Ser2 to Thr2 substitution, which was suggested to be responsible for the weak bioactivities of SRTd [( Thr2,Ile19]SRTb) 5.
Analysis of the venom of Atractaspis microlepidota microlepidota revealed several new SRTX molecules manifesting some new structural and functional characteristics. These novel SRTXs are longer by three amino acids than the previously described SRTXs, and are designated here “long-SRTXs”. Six isoforms, derived from new poly-cistronic precursors, have been identified so far in the venom of this snake. One of these isoforms, designated SRTX-m, was chemically synthesized and its biological properties were studied. Results show that SRTX-m induces toxicity in mice, mostly due to vasoconstriction, and also that it has a lower toxicity and potency than the more potent SRTX described up to now: sarafotoxin-b (SRTX-b) from A. engaddensis 6.
SRTXs S6: several isotoxins from Atractaspis engaddensis (burrowing asp) venom that affect the heart. Three isotoxins, named SRTXs S6a1, S6b and S6c, with strong cardiotoxic activity were isolated from the venom of a snake, Atractaspis engaddensis. All three SRTXs are homologous peptides (four or less than four residue replacements) consisting of 21 amino acid residues. Their structure and activity is novel among snake venom components 7.
Mode of Action
Two ET-receptor subtypes have been characterized. The ETA receptor, which has a higher affinity for ET-1, ET-2 and sarafotoxin (SX) 6b than for ET-3 or SX6c and the ETB receptor which is non-isopeptide selective . It has been generally assumed that the ETA receptor is located on vascular smooth muscle cells, where it mediates the constrictor responses, and the ETB receptor on the endothelial cell, where it mediates prostacyclin and endothelium-derived relaxing factor (EDRF) release by endothelins. There may also be a third subtype of ET receptor selective for ET-3 and SX6c. The systemic pressor effects of the ET/SX peptides are mediated via ETA receptors, the vasoconstriction in the kidney in vivo may be mediated predominantly via ETB-like receptors 8.
Functions
SRTXs induce toxicity, mostly due to vasoconstriction. S6a and S6c produce both vasodilation and vasoconstriction in the systemic vascular bed and increase lobar vascular resistance and those hindquarters vasodilator responses are mediated, in part, by the release of endothelium-derived relaxing factor 9.
References
1.Kloog Y, Ambar I, Sokolovsky M, Kochva E, Wollberg Z, Bdolah A (1988). Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain. Science, 242(4876):268-270
2.Lauer-Fields JL, Cudic M, Wei S, Mari F, Fields GB, Brew K (2007). Engineered Sarafotoxins as Tissue Inhibitor of Metalloproteinases-like Matrix Metalloproteinase Inhibitors. J. Biol. Chem., 282(37):26948-26955.
3.Takasaki C, Yanagisawa M, Kimura S, Goto K, Masaki T (1988). Similarity of endothelin to snake venom toxin. 1988. Nature, 335(6188):303.
4.Sokolovsky M, Galron R, Kloog Y , Bdolah A, Indig FE, Blumberg S, Fleminger G (1990). Endothelins are more sensitive than sarafotoxins to neutral endopeptidase: Possible physiological significance (neutral endopeptidase /proteolysis /receptor binding sites/inositol phospholipid turnover/structure activity relationship). PNAS., 87:4702-4706.
5.Takasaki C, Aimoto S, Kitazumi K, Tasaka K, Shiba T, Nishiki K, Furukawa Y, Takayanagi R, Ohnaka K, and Nawata H (1991). Structure-activity relationships of sarafotoxins: chemical syntheses of chimera peptides of sarafotoxins S6b and S6c. Euro J pharmacol.,198(2-3):165-169.
6.Hayashi MA, Ligny-Lemaire C, Wollberg Z, Wery M, Galat A, Ogawa T, Muller BH, Lamthanh H, Doljansky Y, Bdolah A, Stöcklin R, Ducancel F(2004). Long-sarafotoxins: characterization of a new family of endothelin-like peptides. Peptides, 25(8):1243-1251.
7.Takasaki C, Tamiya N, Bdolah A, Wollberg Z, Kochva E (1988). Sarafotoxins S6: Several isotoxins from Atractaspis engaddensis (burrowing asp) venom that affect the heart. Toxicon., 26(6):543-548.
8.Cristol JP, Warner TD, Thiemermann C, Vane JR (1993). Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br. J. Pharmacol., 108(3):776-779.
9.Minkes RK, Bellan JA, Higuera TR, Kadowitz PJ. (1992). Comparison of responses to sarafotoxins 6a and 6c in pulmonary and systemic vascular beds. Am J Physiol., 262:852-861.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Tuesday, November 17, 2009
Friday, November 13, 2009
Salusin Peptides
Definition
A bioinformatic analysis of full-length, enriched human cDNA libraries searching for previously unidentified bioactive peptides resulted in the identification and characterization of two related peptides of 28 and 20 amino acids, which were designated salusin- and salusin- 1.
Related Peptides
Salusins are translated from an alternatively spliced mRNA of TOR2A, a gene encoding a protein of the torsion dystonia family 1.
Discovery
Shichiri et al., reported the discovery of Salusin peptides with hemodynamic and mitogenic activities in 2003 1.
Structural Characteristics
Salusin-a was predicted to be a 28-residue peptide with an amidated carboxyl-terminus, while salusin-ß was predicted to be a 20-residue peptide with a free carboxyl-terminus.
Their amino acid sequences are:
Salusin-a:SGALPPAPAAPRPALRAQRAGPAGPGAK-NH2
Salusin-ß:AIFIFIRWLLKLGHHGRAPP-NH2 1.
Mode of Action
Salusin-a and -ß did not directly affect cardiac function in the rat heart but that they improved calcium uptake and protein synthesis in neonatal rat cardiomyocytes through the calcium, calcineurin, MAPK and PKC signal pathways 2. Human salusin-ß is a surrogate ligand of the mouse MrgA1 and raises a cautionary flag for experiments that analyze the pharmacological profiles of mas-like G protein-coupled receptors from different species 3.
Functions
Intravenous administration of salusin-a or salusin-ß to rats causes rapid, profound hypotension and bradycardia. Salusins increase intracellular Ca2+, upregulate a variety of genes and induce cell mitogenesis. Salusin-ß stimulates the release of arginine-vasopressin from rat pituitary. Expression of TOR2A mRNA and its splicing into preprosalusin are ubiquitous and immunoreactive salusin-a and salusin-ß are detected in many human tissues, plasma and urine, suggesting that salusins are endocrine and/or paracrine factors 1.
References
1.Shichiri M, Ishimaru S, Ota T, Nishikawa T, Isogai T, Hirata Y (2003). Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities. Nat Med., 9(9):1166-1172.
2.Yu F, Zhao J, Yang J, Gen B, Wang S, Feng X, Tang C, Chang L (2004). Salusins promote cardiomyocyte growth but does not affect cardiac function in rats. Regul Pept., 122(3):191-197
3.Wang Z, Takahashi T, Saito Y, Nagasaki H, Ly NK, Nothacker HP, Reinscheid RK, Yang J, Chang JK, Shichiri M, Civelli O (2006). Salusin ß is a surrogate ligand of the mas-like G protein-coupled receptor MrgA1. Eur J Pharmacol., 539(3):145-150.

For more detail regarding Peptide please visit here : Custom Peptide Synthesis
A bioinformatic analysis of full-length, enriched human cDNA libraries searching for previously unidentified bioactive peptides resulted in the identification and characterization of two related peptides of 28 and 20 amino acids, which were designated salusin- and salusin- 1.
Related Peptides
Salusins are translated from an alternatively spliced mRNA of TOR2A, a gene encoding a protein of the torsion dystonia family 1.
Discovery
Shichiri et al., reported the discovery of Salusin peptides with hemodynamic and mitogenic activities in 2003 1.
Structural Characteristics
Salusin-a was predicted to be a 28-residue peptide with an amidated carboxyl-terminus, while salusin-ß was predicted to be a 20-residue peptide with a free carboxyl-terminus.
Their amino acid sequences are:
Salusin-a:SGALPPAPAAPRPALRAQRAGPAGPGAK-NH2
Salusin-ß:AIFIFIRWLLKLGHHGRAPP-NH2 1.
Mode of Action
Salusin-a and -ß did not directly affect cardiac function in the rat heart but that they improved calcium uptake and protein synthesis in neonatal rat cardiomyocytes through the calcium, calcineurin, MAPK and PKC signal pathways 2. Human salusin-ß is a surrogate ligand of the mouse MrgA1 and raises a cautionary flag for experiments that analyze the pharmacological profiles of mas-like G protein-coupled receptors from different species 3.
Functions
Intravenous administration of salusin-a or salusin-ß to rats causes rapid, profound hypotension and bradycardia. Salusins increase intracellular Ca2+, upregulate a variety of genes and induce cell mitogenesis. Salusin-ß stimulates the release of arginine-vasopressin from rat pituitary. Expression of TOR2A mRNA and its splicing into preprosalusin are ubiquitous and immunoreactive salusin-a and salusin-ß are detected in many human tissues, plasma and urine, suggesting that salusins are endocrine and/or paracrine factors 1.
References
1.Shichiri M, Ishimaru S, Ota T, Nishikawa T, Isogai T, Hirata Y (2003). Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities. Nat Med., 9(9):1166-1172.
2.Yu F, Zhao J, Yang J, Gen B, Wang S, Feng X, Tang C, Chang L (2004). Salusins promote cardiomyocyte growth but does not affect cardiac function in rats. Regul Pept., 122(3):191-197
3.Wang Z, Takahashi T, Saito Y, Nagasaki H, Ly NK, Nothacker HP, Reinscheid RK, Yang J, Chang JK, Shichiri M, Civelli O (2006). Salusin ß is a surrogate ligand of the mas-like G protein-coupled receptor MrgA1. Eur J Pharmacol., 539(3):145-150.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
PKA (Protein Kinase A)
Definition
Protein kinase A (PKA) refers to a family of enzymes whose activity is dependent on the level of cyclic AMP (cAMP) in the cell. PKA is also known as cAMP-dependent protein kinase. PKA is a member of the Ser/Thr protein kinase family, which is involved in the regulation of a large number of processes, including cell proliferation and metabolism, as well as higher level functions of learning and memory 1.
Structural Characteristics
Unlike many protein kinases, the catalytic and regulatory functions of PKA are on separate polypeptide chains. The catalytic (C) subunits are responsible for catalyzing phosphoryl transfer, whereas the regulatory (R) subunits confer cAMP dependence and localize the holoenzyme to discrete subcellular locations via interactions with protein kinase A anchoring proteins2. At low intracellular cAMP concentrations, PKA is maintained as an inactive tetrameric holoenzyme complex (R2C2) consisting of a homodimeric R2 subunit and two C subunits. When intracellular concentrations of cAMP are increased in response to specific stimuli, two cAMP molecules bind allosterically to each R subunit, which releases inhibition of the C subunits and allows them to phosphorylate their protein targets.
There are four major isoforms of PKA that differ with respect to their R subunits (RIa, RIß, RIIa, and RIIß). These isoforms have different biological functions, as determined by genetic studies using mice 3.
Mode of Action
PKA holoenzyme is one of the major receptors for cAMP, where an extracellular stimulus is translated into a signaling response. It is found that the RI regulatory subunit upon binding to the catalytic subunit, RI undergoes a dramatic conformational change in which the two cAMP-binding domains uncouple and wrap around the large lobe of the catalytic subunit. This large conformational reorganization reveals the concerted mechanism required to bind and inhibit the catalytic subunit. Furthermore, the structure also reveals a holoenzyme-specific salt bridge between two conserved residues, Glu261 and Arg366, which tethers the two adenine capping residues far from their cAMP-binding sites. Mutagenesis of these residues demonstrates their importance for PKA activation. These structural insights, combined with the mutagenesis results, provide a molecular mechanism for the ordered and cooperative activation of PKA by cAMP 4.
Functions
Molecular Mechanisms for PKA Mediated Modulation of Immune Function: In lymphocytes, phosphorylation by PKA has been demonstrated to regulate antigen receptor-induced signalling both by altering protein-protein interactions and by changing the enzymatic activity of target proteins. PKA substrates involved in immune activation include transcription factors, members of the MAP kinase pathway and phospholipases. The ability of PKA type I to regulate activation of signalling components important for formation of the immunological synapse, demonstrates that the cAMP signalling pathway can directly modulate proximal events in lymphocyte activation. Furthermore, the recent discovery that PKA regulates Src kinases through modulation of Csk, supports the notion that PKA is involved in the fine-tuning of immune receptor signalling in lipid rafts 5.
PKA Deficiency Causes Axially Localized Neural Tube Defects in Mice: A study has investigated the function of PKA during embryonic development using a PKA-deficient mouse that retains only one functional catalytic subunit allele, either Ca or Cß, of PKA. It has been shown that the reduced PKA activity results in neural tube defects that are specifically localized posterior to the forelimb buds and lead to spina bifida. The affected neural tube has closed appropriately but exhibits an enlarged lumen and abnormal neuroepithelium. Furthermore, decreased PKA activity causes dorsal expansion of Sonic hedgehog signal response in the thoracic to sacral regions correlating with the regions of morphological abnormalities. Other regions of the neural tube appear normal. The regional sensitivity to changes in PKA activity indicates that downstream signaling pathways differ along the anterior-posterior axis and suggesting a functional role for PKA activation in neural tube development 6.
Genetically Lean Mice Result from Targeted Disruption of the RIIß Subunit of PKA: In mice, RIIß isoform is abundant in brown and white adipose tissue and brain, with limited expression elsewhere. To elucidate, a study investigated the function by generating RIIß knockout mice. It as been reported that mutants appear healthy but have markedly diminished white adipose tissue despite normal food intake. They are protected against developing diet-induced obesity and fatty livers. Further it has been sown that mutant brown adipose tissue exhibits a compensatory increase in RIa, which almost entirely replaces lost RIIß, generating an isoform switch. These results demonstrate a role for the RIIß holoenzyme in regulating energy balance and adiposity 3.
References
1.Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS & Stratakis CA (2000). Mutations of the gene encoding the protein kinase A type I-a regulatory subunit in patients with the Carney complex. Nat. Genet., 26:89–92.
2. Wong W, Scott JD (2004). AKAP signalling complexes: focal points in space and time. Nat. Rev. Mol. Cell. Biol., 5:959–970.
3.Cummings DE, Brandon EP, Planas JV, Motamed K, Idzerda RL and McKnight GS. (1996). Genetically lean mice result from targeted disruption of the RIIß subunit of protein kinase A. Nature, 382: 622–626.
4.Kim C, Cheng CY, Saldanha SA, Taylor SS (2007). PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation. Cell, 130(6):1032-1043.
5.Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Taskén K (2002). Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal, 14(1):1-9.
6.Huang Y, Roelink H, McKnight GS (2002). Protein kinase A deficiency causes axially localized neural tube defects in mice. J. Biol. Chem., 277(22):19889-19896.


For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Protein kinase A (PKA) refers to a family of enzymes whose activity is dependent on the level of cyclic AMP (cAMP) in the cell. PKA is also known as cAMP-dependent protein kinase. PKA is a member of the Ser/Thr protein kinase family, which is involved in the regulation of a large number of processes, including cell proliferation and metabolism, as well as higher level functions of learning and memory 1.
Structural Characteristics
Unlike many protein kinases, the catalytic and regulatory functions of PKA are on separate polypeptide chains. The catalytic (C) subunits are responsible for catalyzing phosphoryl transfer, whereas the regulatory (R) subunits confer cAMP dependence and localize the holoenzyme to discrete subcellular locations via interactions with protein kinase A anchoring proteins2. At low intracellular cAMP concentrations, PKA is maintained as an inactive tetrameric holoenzyme complex (R2C2) consisting of a homodimeric R2 subunit and two C subunits. When intracellular concentrations of cAMP are increased in response to specific stimuli, two cAMP molecules bind allosterically to each R subunit, which releases inhibition of the C subunits and allows them to phosphorylate their protein targets.
There are four major isoforms of PKA that differ with respect to their R subunits (RIa, RIß, RIIa, and RIIß). These isoforms have different biological functions, as determined by genetic studies using mice 3.
Mode of Action
PKA holoenzyme is one of the major receptors for cAMP, where an extracellular stimulus is translated into a signaling response. It is found that the RI regulatory subunit upon binding to the catalytic subunit, RI undergoes a dramatic conformational change in which the two cAMP-binding domains uncouple and wrap around the large lobe of the catalytic subunit. This large conformational reorganization reveals the concerted mechanism required to bind and inhibit the catalytic subunit. Furthermore, the structure also reveals a holoenzyme-specific salt bridge between two conserved residues, Glu261 and Arg366, which tethers the two adenine capping residues far from their cAMP-binding sites. Mutagenesis of these residues demonstrates their importance for PKA activation. These structural insights, combined with the mutagenesis results, provide a molecular mechanism for the ordered and cooperative activation of PKA by cAMP 4.
Functions
Molecular Mechanisms for PKA Mediated Modulation of Immune Function: In lymphocytes, phosphorylation by PKA has been demonstrated to regulate antigen receptor-induced signalling both by altering protein-protein interactions and by changing the enzymatic activity of target proteins. PKA substrates involved in immune activation include transcription factors, members of the MAP kinase pathway and phospholipases. The ability of PKA type I to regulate activation of signalling components important for formation of the immunological synapse, demonstrates that the cAMP signalling pathway can directly modulate proximal events in lymphocyte activation. Furthermore, the recent discovery that PKA regulates Src kinases through modulation of Csk, supports the notion that PKA is involved in the fine-tuning of immune receptor signalling in lipid rafts 5.
PKA Deficiency Causes Axially Localized Neural Tube Defects in Mice: A study has investigated the function of PKA during embryonic development using a PKA-deficient mouse that retains only one functional catalytic subunit allele, either Ca or Cß, of PKA. It has been shown that the reduced PKA activity results in neural tube defects that are specifically localized posterior to the forelimb buds and lead to spina bifida. The affected neural tube has closed appropriately but exhibits an enlarged lumen and abnormal neuroepithelium. Furthermore, decreased PKA activity causes dorsal expansion of Sonic hedgehog signal response in the thoracic to sacral regions correlating with the regions of morphological abnormalities. Other regions of the neural tube appear normal. The regional sensitivity to changes in PKA activity indicates that downstream signaling pathways differ along the anterior-posterior axis and suggesting a functional role for PKA activation in neural tube development 6.
Genetically Lean Mice Result from Targeted Disruption of the RIIß Subunit of PKA: In mice, RIIß isoform is abundant in brown and white adipose tissue and brain, with limited expression elsewhere. To elucidate, a study investigated the function by generating RIIß knockout mice. It as been reported that mutants appear healthy but have markedly diminished white adipose tissue despite normal food intake. They are protected against developing diet-induced obesity and fatty livers. Further it has been sown that mutant brown adipose tissue exhibits a compensatory increase in RIa, which almost entirely replaces lost RIIß, generating an isoform switch. These results demonstrate a role for the RIIß holoenzyme in regulating energy balance and adiposity 3.
References
1.Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS & Stratakis CA (2000). Mutations of the gene encoding the protein kinase A type I-a regulatory subunit in patients with the Carney complex. Nat. Genet., 26:89–92.
2. Wong W, Scott JD (2004). AKAP signalling complexes: focal points in space and time. Nat. Rev. Mol. Cell. Biol., 5:959–970.
3.Cummings DE, Brandon EP, Planas JV, Motamed K, Idzerda RL and McKnight GS. (1996). Genetically lean mice result from targeted disruption of the RIIß subunit of protein kinase A. Nature, 382: 622–626.
4.Kim C, Cheng CY, Saldanha SA, Taylor SS (2007). PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation. Cell, 130(6):1032-1043.
5.Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Taskén K (2002). Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal, 14(1):1-9.
6.Huang Y, Roelink H, McKnight GS (2002). Protein kinase A deficiency causes axially localized neural tube defects in mice. J. Biol. Chem., 277(22):19889-19896.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Procollagen Fragments
Definition
Procollagen is the soluble precursor of collagen possibly formed by fibroblasts in the process of collagen synthesis.
Discovery
While studying collagen synthesized by human skin fibroblasts in culture, Layman et al., found that these cells secreted an unusual collagen into the medium that was more soluble than normal collagen and that, upon denaturation, yielded components larger than a chains. Incubation with pepsin caused a limited digestion that converted this protein into a collagen-like molecule. They suggested that this medium protein was a precursor form of collagen possibly involved in transport 1.
Structural Characteristics
Recent reports that biosynthetic precursors of both al and a 2 chains ("procollagens": "pro al", and "pro a2") may be extracted from embryonic rat 2 and chick 3 calvaria, and may be found in the medium of cultured fibroblasts1 and cultured embryonic-chick tendon cells. The procollagens have been characterized as native al and a2 chains with additional terminal peptide sequences of molecular weight about 1.5-2.0 kDa. Noncovalently assembled chains might be stabilized by formation of disulfide bonds between cysteine residues in these extra peptide sequences. In bone culture preparations pro al contains 5 or 6 half-cystine residues per chain, but little or no cysteine was detected in pro a2, and no evidence for disulfide- bond formation between procollagen chains was obtained 4. In contrast, in preparations of cultured fibroblasts 1 and tendon cells 5, data from molecular sieve chromatography gave evidence for association of procollagen chains. In particular, the results of Dehm et al., raised the possibility that three procollagen chains might be assembled through disulfidebonds5. Procollagen, the triple-stranded precursor of chick embryo skull bone collagen, contains two pro a1 and one pro ß2 chains.Physiologically the NH2-peptides are cut off to give an intermediate called altered procollagen (ALT), and subsequent removal of its COOH-peptides yields collagen.
Mode of Action
In a study, incubation of rat calvaria for short times in the presence of a labeled amino acid revealed the existence of a collagen fraction (procollagen) that functions as a biosynthetic precursor of collagen. Procollagen contains an al-like chain (pre-al) that elutes earlier from cellulose than does rat-bone ?l and has a molecular weight, estimated by acrylamide gel electrophoresis, of 120,000. Furthermore, a time-dependent conversion of pre-al to al was demonstrated by incubation of calvaria for periods varying from 9 to 60 min and by a pulse-chase experiment. Limited cleavage of procollagen with pepsin resulted in a molecule with a chain resembling al in chromatographic properties, molecular weight, and relative hydroxyproline and proline contents. Thus, conversion of procollagen to collagen is likely to occur in vivo by a proteolytic mechanism. The additional peptide sequences in procollagen may serve to initiate chain association in triple-helix formation, to facilitate molecular transport, and to inhibit intracellular fibrogenesis 2.
Functions
Defect in Conversion of Procollagen to Collagen in a form of Ehlers-Danlos Syndrome: Three patients with a form of the Ehlers-Danlos syndrome, a generalized disorder of connective tissue, have detectable amounts of procollagen in extracts of their skin and tendon. The activity of procollagen peptidase, the enzyme that converts procollagen to collagen, is reduced in cultures of fibroblasts. The clinical manifestations of this syndrome may be related to impaired enzymatic conversion of procollagen to collagen. Cultures of skin fibroblasts from these patients have an increased rate of synthesis of collagenous protein (collagen and procollagen), possibly related to the inability of these cells to convert procollagen to collagen 6.
References
1.Layman DL, McGoodwin EB, Martin GR (1971). The Nature of the Collagen Synthesized by Cultured Human Fibroblasts. PNAS, 68(2):454-458.
2.Bellamy G, Bornstein P (1971). Evidence for procollagen, a biosynthetic precursor of collagen. PNAS., 68:1138-1142.
3.Muller PK, McGoodwin E, Martin GR (1971). Studies on protocollagen: identification of a precursor of proto alpha 1. Biochem. Biophys. Res. Commun., 44:110-116.
4.Bornstein P, Von Der Mark K, Wyke AW, Ehrlich HP, Monson JM (1972). Characterization of the Pro-a1 Chain of Procollagen. J. Biol. Chem., 247:2808-2813.
5.Dehm P, Jimenez S A, Olse BR, Prockop DJ (1972). A transport form of collagen from embryonic tendon: electron microscopic demonstration of an NH 2 -terminal extension and evidence suggesting the presence of cystine in the molecule (chick embryo-tropocollagen-gel filtration). PNAS, 69(1):60-64.
6.Lichtenstein JR, Martin GR, Kohn LD, Byers PH, McKusick VA (1973). Defect in Conversion of Procollagen to Collagen in a Form of Ehlers-Danlos Syndrome. Science, 182(109):298-300.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Procollagen is the soluble precursor of collagen possibly formed by fibroblasts in the process of collagen synthesis.
Discovery
While studying collagen synthesized by human skin fibroblasts in culture, Layman et al., found that these cells secreted an unusual collagen into the medium that was more soluble than normal collagen and that, upon denaturation, yielded components larger than a chains. Incubation with pepsin caused a limited digestion that converted this protein into a collagen-like molecule. They suggested that this medium protein was a precursor form of collagen possibly involved in transport 1.
Structural Characteristics
Recent reports that biosynthetic precursors of both al and a 2 chains ("procollagens": "pro al", and "pro a2") may be extracted from embryonic rat 2 and chick 3 calvaria, and may be found in the medium of cultured fibroblasts1 and cultured embryonic-chick tendon cells. The procollagens have been characterized as native al and a2 chains with additional terminal peptide sequences of molecular weight about 1.5-2.0 kDa. Noncovalently assembled chains might be stabilized by formation of disulfide bonds between cysteine residues in these extra peptide sequences. In bone culture preparations pro al contains 5 or 6 half-cystine residues per chain, but little or no cysteine was detected in pro a2, and no evidence for disulfide- bond formation between procollagen chains was obtained 4. In contrast, in preparations of cultured fibroblasts 1 and tendon cells 5, data from molecular sieve chromatography gave evidence for association of procollagen chains. In particular, the results of Dehm et al., raised the possibility that three procollagen chains might be assembled through disulfidebonds5. Procollagen, the triple-stranded precursor of chick embryo skull bone collagen, contains two pro a1 and one pro ß2 chains.Physiologically the NH2-peptides are cut off to give an intermediate called altered procollagen (ALT), and subsequent removal of its COOH-peptides yields collagen.
Mode of Action
In a study, incubation of rat calvaria for short times in the presence of a labeled amino acid revealed the existence of a collagen fraction (procollagen) that functions as a biosynthetic precursor of collagen. Procollagen contains an al-like chain (pre-al) that elutes earlier from cellulose than does rat-bone ?l and has a molecular weight, estimated by acrylamide gel electrophoresis, of 120,000. Furthermore, a time-dependent conversion of pre-al to al was demonstrated by incubation of calvaria for periods varying from 9 to 60 min and by a pulse-chase experiment. Limited cleavage of procollagen with pepsin resulted in a molecule with a chain resembling al in chromatographic properties, molecular weight, and relative hydroxyproline and proline contents. Thus, conversion of procollagen to collagen is likely to occur in vivo by a proteolytic mechanism. The additional peptide sequences in procollagen may serve to initiate chain association in triple-helix formation, to facilitate molecular transport, and to inhibit intracellular fibrogenesis 2.
Functions
Defect in Conversion of Procollagen to Collagen in a form of Ehlers-Danlos Syndrome: Three patients with a form of the Ehlers-Danlos syndrome, a generalized disorder of connective tissue, have detectable amounts of procollagen in extracts of their skin and tendon. The activity of procollagen peptidase, the enzyme that converts procollagen to collagen, is reduced in cultures of fibroblasts. The clinical manifestations of this syndrome may be related to impaired enzymatic conversion of procollagen to collagen. Cultures of skin fibroblasts from these patients have an increased rate of synthesis of collagenous protein (collagen and procollagen), possibly related to the inability of these cells to convert procollagen to collagen 6.
References
1.Layman DL, McGoodwin EB, Martin GR (1971). The Nature of the Collagen Synthesized by Cultured Human Fibroblasts. PNAS, 68(2):454-458.
2.Bellamy G, Bornstein P (1971). Evidence for procollagen, a biosynthetic precursor of collagen. PNAS., 68:1138-1142.
3.Muller PK, McGoodwin E, Martin GR (1971). Studies on protocollagen: identification of a precursor of proto alpha 1. Biochem. Biophys. Res. Commun., 44:110-116.
4.Bornstein P, Von Der Mark K, Wyke AW, Ehrlich HP, Monson JM (1972). Characterization of the Pro-a1 Chain of Procollagen. J. Biol. Chem., 247:2808-2813.
5.Dehm P, Jimenez S A, Olse BR, Prockop DJ (1972). A transport form of collagen from embryonic tendon: electron microscopic demonstration of an NH 2 -terminal extension and evidence suggesting the presence of cystine in the molecule (chick embryo-tropocollagen-gel filtration). PNAS, 69(1):60-64.
6.Lichtenstein JR, Martin GR, Kohn LD, Byers PH, McKusick VA (1973). Defect in Conversion of Procollagen to Collagen in a Form of Ehlers-Danlos Syndrome. Science, 182(109):298-300.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Platelet Factor 4 Fragments
Definition
Platelet factor 4 (Platelet heparin-neutralizing factor) is present in blood platelets as a proteoglycan and is released by platelets during coagulation, binds very tightly to negatively charged oligosaccharides such as heparin.
Discovery
Human platelets contain a releasable low molecular weight protein which can neutralize heparin’s anticoagulant effect. This heparin-neutralizing protein, referred to as Platelet Factor Four, was first postulated by Conley et al., following clinical observations of heparin’s prolonged effect in thrombocytopenic patients 1.
Fragments
Platelet factor 4 fragment induces histamine release from rat peritoneal mast cells. In a study, the effect of PF-4 on histamine release from rat peritoneal mast cells was investigated by employing its biologically-active carboxyl-terminal fragment, PF-4 (58-70). It was found that PF-4 (58-70) stimulated histamine release from mast cells in a dose-dependent manner (10(-8) to 10(-5) M). Histamine release induced by PF-4 (58-70) occurred rapidly (<30s)>
Structural Characteristics
PF-4 belongs to the C-X-C chemokine family. This family also includes interleukin-8 (IL-8), ß-thromboglobulin, neutrophil-activating protein, interferon-inducing protein 10 (IP-10), and melanocyte growth-stimulating activity. PF-4 is a 7.8 kDaÅ protein of 70 amino acid length3. The crystal structure of human PF-4 has been solved to a resolution of 2.4 Å by molecular replacement4. The N-terminal residues form antiparallel ß-sheet-like structures. A positively charged ring of lysine and arginine side chains encircles the PF-4 molecule presenting multiple potential sites for heparin binding.
Mode of Action
The heparin-neutralizing activity in platelets is localized in the a granules. It is bound to a chondroitin 4-sulfate proteoglycan carrier with molecular weight of 5.9 kDa. PF4 is actively released during platelet aggregation induced by collagen, thrombin, adenosine diphosphate and epinephrine. The COOH-terminal is unusual and seemed a likely binding site for glycosaminoglycans. In a study it was observed that the COOH-terminal tryptic peptide in high concentration partially reversed the prolonged thrombin time induced by heparin 5, suggesting heparin binding was localized to the COOH-terminal region of PF4. Support for the involvement of these lysines in the PF4-heparin binding activity was provided by the work of Handin and Cohen who showed that guanidination of lysines in PF4 decreased heparin neutralizing activity, but that modification of arginines was without effect 6.
Functions
PF-4 Modulates Fibroblast Growth Factor 2 Activity and Inhibits Fgf-2 Dimerization: A study investigated the mechanism of inhibition by examining the interaction of PF-4 and the fibroblast growth factor-2 (FGF-2)/fibroblast growth factor receptor (FGFR) system. PF-4 inhibited the binding of FGF-2 to high-affinity and low-affinity binding sites in murine microvascular endothelial cells (LEII cells) and proliferation. Maximum inhibition of binding to endothelial FGF receptors was observed at PF-4 concentrations between 5 and 10 µg/mL (half maximum inhibition at 0.6 µg/mL), and proliferation was completely inhibited at 2 µg/mL. Furthermore, to gain insight into the mechanism of inhibition, analysis of interaction of PF-4 with FGF-2/FGFR by using mutant heparan sulfate-deficient Chinese hamster ovary (CHO) cells transfected with the FGFR-1 cDNA (CHOm-FGFR-1) and the direct interaction with FGF-2 was conducted. It was found that in the absence of heparin, PF-4 inhibited binding of 125I-FGF-2 to CHOm-FGFR-1 cells in a concentration-dependent manner, although not completely. In the presence of heparin, PF-4 abolished totally the stimulatory effect of heparin. Furthermore, PF-4 complexed to FGF-2 and inhibited endogenous or heparin-induced FGF-2 dimerization. These results indicate that PF-4 interacts with FGF-2 by complex formation, inhibiting FGF-2 dimerization, binding to FGF receptors, and internalization. This mechanism most likely contributes to the antiangiogenic properties 7of PF-4.
PF-4 Binds to Interleukin 8 Receptors and Activates Neutrophils When its N Terminus is Modified with Glu-Leu-Arg: Amino acid deletion and mutagenesis experiments have indicated that the sequences Glu-Leu-Arg (ELR) preceding the first cysteine at the N terminus of interleukin 8 (IL-8) is required for receptor binding and neutrophil activation. Platelet factor 4 (PF4) is structurally related to IL-8 (35% sequence identity) but lacks the N-terminal ELR sequence and comparable effects on neutrophils. In a study the ELR sequence was introduced at the N terminus of PF4 and found that the modified protein was a potent neutrophil activator and attractant. On the other hand, when the ELR sequence was introduced into the corresponding positions of two other proteins related to IL-8, gamma-interferon-inducible protein IP10 and monocyte chemoattractant protein 1, neither of them acquired neutrophil-activating properties, indicating that besides ELR additional structural determinants of IL-8 and PF4 are important for binding to IL-8 receptors. The conservation of these binding determinants suggests that PF4 may have evolved from a neutrophil activating protein 8.
References
1.Conley CL, Hartmann RC & Lalley JS (1948). The relationship of heparin activity to platelet concentration. Proc. Soc. Exp. Biol. Med ., 69(2):284-287.
2.Suzuki R, Kimura T, Kitaichi K, Tatsumi Y, Matsushima M, Zhao YL, Shibata E, Baba K, Hasegawa T, Takagi K (2002). Platelet factor 4 fragment induces histamine release from rat peritoneal mast cells. Peptides, 23(10):1713-1717.
3.Deuel TF, Keim PF, Farmer M, Heinrickson RL (1977). Amino acid sequence of human platelet factor 4. PNAS., 74(6):2256-2258.
4.Zhang X, Chen L, Bancroft DL, Lai CK, Maione TM (1994). Crystal structure of recombinant human platelet factor 4. Biochemistry, 33 (27):8361-8316.
5.Huang SS, Huang JS, Deuel TF (1982). Proteoglycan Carrier of Human Platelet Factor 4 – Isolation and characterization. J. Biol. Chem., 257 (19):11546-11550.
6.Handin RI, Cohen HJ (1976). Purification and Binding Properties of Human Platelet Factor Four. J. Biol. Chem., 251(14): 4273-4282.
7.Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A (1998). Platelet Factor 4 Modulates Fibroblast Growth Factor 2 (FGF-2) Activity and Inhibits FGF-2 Dimerization. Blood, 91(9):3289-3299.
8.Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolini M (1993). Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. PNAS., 90(8):3574-3577.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Platelet factor 4 (Platelet heparin-neutralizing factor) is present in blood platelets as a proteoglycan and is released by platelets during coagulation, binds very tightly to negatively charged oligosaccharides such as heparin.
Discovery
Human platelets contain a releasable low molecular weight protein which can neutralize heparin’s anticoagulant effect. This heparin-neutralizing protein, referred to as Platelet Factor Four, was first postulated by Conley et al., following clinical observations of heparin’s prolonged effect in thrombocytopenic patients 1.
Fragments
Platelet factor 4 fragment induces histamine release from rat peritoneal mast cells. In a study, the effect of PF-4 on histamine release from rat peritoneal mast cells was investigated by employing its biologically-active carboxyl-terminal fragment, PF-4 (58-70). It was found that PF-4 (58-70) stimulated histamine release from mast cells in a dose-dependent manner (10(-8) to 10(-5) M). Histamine release induced by PF-4 (58-70) occurred rapidly (<30s)>
Structural Characteristics
PF-4 belongs to the C-X-C chemokine family. This family also includes interleukin-8 (IL-8), ß-thromboglobulin, neutrophil-activating protein, interferon-inducing protein 10 (IP-10), and melanocyte growth-stimulating activity. PF-4 is a 7.8 kDaÅ protein of 70 amino acid length3. The crystal structure of human PF-4 has been solved to a resolution of 2.4 Å by molecular replacement4. The N-terminal residues form antiparallel ß-sheet-like structures. A positively charged ring of lysine and arginine side chains encircles the PF-4 molecule presenting multiple potential sites for heparin binding.
Mode of Action
The heparin-neutralizing activity in platelets is localized in the a granules. It is bound to a chondroitin 4-sulfate proteoglycan carrier with molecular weight of 5.9 kDa. PF4 is actively released during platelet aggregation induced by collagen, thrombin, adenosine diphosphate and epinephrine. The COOH-terminal is unusual and seemed a likely binding site for glycosaminoglycans. In a study it was observed that the COOH-terminal tryptic peptide in high concentration partially reversed the prolonged thrombin time induced by heparin 5, suggesting heparin binding was localized to the COOH-terminal region of PF4. Support for the involvement of these lysines in the PF4-heparin binding activity was provided by the work of Handin and Cohen who showed that guanidination of lysines in PF4 decreased heparin neutralizing activity, but that modification of arginines was without effect 6.
Functions
PF-4 Modulates Fibroblast Growth Factor 2 Activity and Inhibits Fgf-2 Dimerization: A study investigated the mechanism of inhibition by examining the interaction of PF-4 and the fibroblast growth factor-2 (FGF-2)/fibroblast growth factor receptor (FGFR) system. PF-4 inhibited the binding of FGF-2 to high-affinity and low-affinity binding sites in murine microvascular endothelial cells (LEII cells) and proliferation. Maximum inhibition of binding to endothelial FGF receptors was observed at PF-4 concentrations between 5 and 10 µg/mL (half maximum inhibition at 0.6 µg/mL), and proliferation was completely inhibited at 2 µg/mL. Furthermore, to gain insight into the mechanism of inhibition, analysis of interaction of PF-4 with FGF-2/FGFR by using mutant heparan sulfate-deficient Chinese hamster ovary (CHO) cells transfected with the FGFR-1 cDNA (CHOm-FGFR-1) and the direct interaction with FGF-2 was conducted. It was found that in the absence of heparin, PF-4 inhibited binding of 125I-FGF-2 to CHOm-FGFR-1 cells in a concentration-dependent manner, although not completely. In the presence of heparin, PF-4 abolished totally the stimulatory effect of heparin. Furthermore, PF-4 complexed to FGF-2 and inhibited endogenous or heparin-induced FGF-2 dimerization. These results indicate that PF-4 interacts with FGF-2 by complex formation, inhibiting FGF-2 dimerization, binding to FGF receptors, and internalization. This mechanism most likely contributes to the antiangiogenic properties 7of PF-4.
PF-4 Binds to Interleukin 8 Receptors and Activates Neutrophils When its N Terminus is Modified with Glu-Leu-Arg: Amino acid deletion and mutagenesis experiments have indicated that the sequences Glu-Leu-Arg (ELR) preceding the first cysteine at the N terminus of interleukin 8 (IL-8) is required for receptor binding and neutrophil activation. Platelet factor 4 (PF4) is structurally related to IL-8 (35% sequence identity) but lacks the N-terminal ELR sequence and comparable effects on neutrophils. In a study the ELR sequence was introduced at the N terminus of PF4 and found that the modified protein was a potent neutrophil activator and attractant. On the other hand, when the ELR sequence was introduced into the corresponding positions of two other proteins related to IL-8, gamma-interferon-inducible protein IP10 and monocyte chemoattractant protein 1, neither of them acquired neutrophil-activating properties, indicating that besides ELR additional structural determinants of IL-8 and PF4 are important for binding to IL-8 receptors. The conservation of these binding determinants suggests that PF4 may have evolved from a neutrophil activating protein 8.
References
1.Conley CL, Hartmann RC & Lalley JS (1948). The relationship of heparin activity to platelet concentration. Proc. Soc. Exp. Biol. Med ., 69(2):284-287.
2.Suzuki R, Kimura T, Kitaichi K, Tatsumi Y, Matsushima M, Zhao YL, Shibata E, Baba K, Hasegawa T, Takagi K (2002). Platelet factor 4 fragment induces histamine release from rat peritoneal mast cells. Peptides, 23(10):1713-1717.
3.Deuel TF, Keim PF, Farmer M, Heinrickson RL (1977). Amino acid sequence of human platelet factor 4. PNAS., 74(6):2256-2258.
4.Zhang X, Chen L, Bancroft DL, Lai CK, Maione TM (1994). Crystal structure of recombinant human platelet factor 4. Biochemistry, 33 (27):8361-8316.
5.Huang SS, Huang JS, Deuel TF (1982). Proteoglycan Carrier of Human Platelet Factor 4 – Isolation and characterization. J. Biol. Chem., 257 (19):11546-11550.
6.Handin RI, Cohen HJ (1976). Purification and Binding Properties of Human Platelet Factor Four. J. Biol. Chem., 251(14): 4273-4282.
7.Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A (1998). Platelet Factor 4 Modulates Fibroblast Growth Factor 2 (FGF-2) Activity and Inhibits FGF-2 Dimerization. Blood, 91(9):3289-3299.
8.Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolini M (1993). Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. PNAS., 90(8):3574-3577.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
PKC (Protein Kinase C)
Definition
Protein kinase C (PKC) is a family of enzymes that are involved in controlling the function of other proteins through the phosphorylation of hydroxyl groups of serine and threonine amino acid residues on these proteins.
Related Peptides
To date, 11 protein kinase C isozymes have been identified and classified into three groups cPKC, nPKC, and aPKC, based on their structure and cofactor regulation. The best characterized and first discovered are the conventional protein kinase Cs: a, two alternatively spliced variants, ßI and ßII, and ?. This class distinguishes itself from the others in that function is regulated by Ca2+; its C2 domain contains a putative Ca2+-binding site. The next well characterized are the novel protein kinase Cs: d, ?, ? (L), ?, and µ. These isozymes are structurally similar to the conventional protein kinase Cs, except that the C2 domain, while maintaining structural residues, does not have the functional groups that appear to mediate Ca2+ binding. The least understood isozymes are the atypical protein kinase Cs: ? and ?. These differ significantly in structure from the other two classes; first, the C1 domain contains only one Cys-rich motif (not two), and second, key residues that maintain the C2 fold do not appear to be present 1.
Structural Characterisitcs
Members of the PKC family are a single polypeptide, comprised of an N-terminal regulatory region (approximately 20-40 kDa) and a C-terminal catalytic region (approximately 45 kDa). Cloning of the first isozymes in the mid-1980s revealed four conserved domains: C1-C. Each is a functional module, and many unrelated proteins have one or the other. The function of each of these domains has been established by extensive biochemical and mutational analysis; the C1 domain contains a Cys-rich motif, duplicated in most isozymes, that forms the diacylglycerol/phorbol ester binding site; this domain is immediately preceded by an autoinhibitory pseudosubstrate sequence; the C2 domain contains the recognition site for acidic lipids and, in some isozymes, the Ca2+-binding site. The C3 and C4 domains form the ATP- and substrate-binding lobes of the kinase core. The regulatory and catalytic halves are separated by a hinge region that becomes proteolytically labile when the enzyme is membrane-bound; the proteolytically generated kinase domain (protein kinase M), freed of inhibition by the pseudosubstrate, is constitutively active 2.
Mode of Action
Diacylglycerol (DAG) Activates PKC: The source of DAG that activates PKC can be derived from the hydrolysis of phosphatidylinositides or from the metabolism of phosphatidylcholine by phospholipase C or D. The principal function of DAG is to activate a family of protein kinases collectively termed PKC. In the absence of hormone stimulation, PKC is present as a soluble cytosolic protein that is catalytically inactive. A rise in the cytosolic Ca2+ level causes protein kinase C to bind to the cytosolic leaflet of the plasma membrane, where the membrane-associated DAG can activate it. Thus activation of PKC depends on an increase of both Ca2+ ions and DAG 3. The activation of PKC in different cells results in a varied array of cellular responses. PKC also phosphorylates various transcription factors; depending on the cell type; these induce synthesis of mRNAs that trigger cell proliferation.
Functions
Cellular and functional alterations in vascular cells induced by DAG-PKC activation: Multiple cellular and functional abnormalities in the diabetic vascular tissues have been attributed to the activation of DAG-PKC pathways. Abnormalities in vascular blood flow and contractility have been found in many organs of diabetic animals or patients, including the kidney, retina, peripheral arteries, and microvessels of peripheral nerves. Multiple lines of evidence have supported that the decreases in retinal blood flow are due to PKC activation. Decreases in retinal blood flow in diabetic rats have been reported to be normalized by PKC inhibitors 4. In addition to the retina, decreases in blood flow have also been reported in the peripheral nerves of diabetic animals that were normalized by PKC inhibition.
Cardiomyopathy
It has been reported that the diabetic state will induce the activation of PKC- isoform in the hearts of rats. To determine whether activation of PKC- isoform can cause cardiac abnormalities, a study was conducted using transgenic mice overexpressing PKC- 2 isoform specifically in the myocardium by the use of tissue-specific promoter myosin heavy chain (MHC). These mice developed cardiac hypertrophy, cardiomyocyte injuries, and fibrosis at 8–12 weeks of life. At the 20th week, cardiac atrophy and severe fibrosis were observed. Treatment with PKC - isoform inhibitor (LY333531) prevented most of the functional and pathological changes in the hearts of the transgenic mice, clearly demonstrating that excessive PKC activation can cause cardiomyopathy6.
References
1.Harry M and Peter J (1998). The extended protein kinase C superfamily. Biochem. J., 332:281-292.
2.Newton AC (1995). Protein Kinase C: Structure, Function, and Regulation. J. Biol.Chem., 270(48):28495-28498.
3.Nishizuka Y (1995). Protein kinase C and lipid signaling for sustained cellular responses. Faseb., 9(7):484-496.
4.Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL (1993). Correlation of diacylglycerol and protein kinase C activity in rat retina to retinal circulation. Am J Physiol., 265:783-793.
5.Wakasaki H, Koya D, Schoen FJ, Jirousek MR, Ways DK, Hoit BD, Walsh RA, King GL (1997). Targeted overexpression of protein kinase C isoform in myocardium causes cardiomyopathy. PNAS., 94(17):9320-9325.



For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Protein kinase C (PKC) is a family of enzymes that are involved in controlling the function of other proteins through the phosphorylation of hydroxyl groups of serine and threonine amino acid residues on these proteins.
Related Peptides
To date, 11 protein kinase C isozymes have been identified and classified into three groups cPKC, nPKC, and aPKC, based on their structure and cofactor regulation. The best characterized and first discovered are the conventional protein kinase Cs: a, two alternatively spliced variants, ßI and ßII, and ?. This class distinguishes itself from the others in that function is regulated by Ca2+; its C2 domain contains a putative Ca2+-binding site. The next well characterized are the novel protein kinase Cs: d, ?, ? (L), ?, and µ. These isozymes are structurally similar to the conventional protein kinase Cs, except that the C2 domain, while maintaining structural residues, does not have the functional groups that appear to mediate Ca2+ binding. The least understood isozymes are the atypical protein kinase Cs: ? and ?. These differ significantly in structure from the other two classes; first, the C1 domain contains only one Cys-rich motif (not two), and second, key residues that maintain the C2 fold do not appear to be present 1.
Structural Characterisitcs
Members of the PKC family are a single polypeptide, comprised of an N-terminal regulatory region (approximately 20-40 kDa) and a C-terminal catalytic region (approximately 45 kDa). Cloning of the first isozymes in the mid-1980s revealed four conserved domains: C1-C. Each is a functional module, and many unrelated proteins have one or the other. The function of each of these domains has been established by extensive biochemical and mutational analysis; the C1 domain contains a Cys-rich motif, duplicated in most isozymes, that forms the diacylglycerol/phorbol ester binding site; this domain is immediately preceded by an autoinhibitory pseudosubstrate sequence; the C2 domain contains the recognition site for acidic lipids and, in some isozymes, the Ca2+-binding site. The C3 and C4 domains form the ATP- and substrate-binding lobes of the kinase core. The regulatory and catalytic halves are separated by a hinge region that becomes proteolytically labile when the enzyme is membrane-bound; the proteolytically generated kinase domain (protein kinase M), freed of inhibition by the pseudosubstrate, is constitutively active 2.
Mode of Action
Diacylglycerol (DAG) Activates PKC: The source of DAG that activates PKC can be derived from the hydrolysis of phosphatidylinositides or from the metabolism of phosphatidylcholine by phospholipase C or D. The principal function of DAG is to activate a family of protein kinases collectively termed PKC. In the absence of hormone stimulation, PKC is present as a soluble cytosolic protein that is catalytically inactive. A rise in the cytosolic Ca2+ level causes protein kinase C to bind to the cytosolic leaflet of the plasma membrane, where the membrane-associated DAG can activate it. Thus activation of PKC depends on an increase of both Ca2+ ions and DAG 3. The activation of PKC in different cells results in a varied array of cellular responses. PKC also phosphorylates various transcription factors; depending on the cell type; these induce synthesis of mRNAs that trigger cell proliferation.
Functions
Cellular and functional alterations in vascular cells induced by DAG-PKC activation: Multiple cellular and functional abnormalities in the diabetic vascular tissues have been attributed to the activation of DAG-PKC pathways. Abnormalities in vascular blood flow and contractility have been found in many organs of diabetic animals or patients, including the kidney, retina, peripheral arteries, and microvessels of peripheral nerves. Multiple lines of evidence have supported that the decreases in retinal blood flow are due to PKC activation. Decreases in retinal blood flow in diabetic rats have been reported to be normalized by PKC inhibitors 4. In addition to the retina, decreases in blood flow have also been reported in the peripheral nerves of diabetic animals that were normalized by PKC inhibition.
Cardiomyopathy
It has been reported that the diabetic state will induce the activation of PKC- isoform in the hearts of rats. To determine whether activation of PKC- isoform can cause cardiac abnormalities, a study was conducted using transgenic mice overexpressing PKC- 2 isoform specifically in the myocardium by the use of tissue-specific promoter myosin heavy chain (MHC). These mice developed cardiac hypertrophy, cardiomyocyte injuries, and fibrosis at 8–12 weeks of life. At the 20th week, cardiac atrophy and severe fibrosis were observed. Treatment with PKC - isoform inhibitor (LY333531) prevented most of the functional and pathological changes in the hearts of the transgenic mice, clearly demonstrating that excessive PKC activation can cause cardiomyopathy6.
References
1.Harry M and Peter J (1998). The extended protein kinase C superfamily. Biochem. J., 332:281-292.
2.Newton AC (1995). Protein Kinase C: Structure, Function, and Regulation. J. Biol.Chem., 270(48):28495-28498.
3.Nishizuka Y (1995). Protein kinase C and lipid signaling for sustained cellular responses. Faseb., 9(7):484-496.
4.Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL (1993). Correlation of diacylglycerol and protein kinase C activity in rat retina to retinal circulation. Am J Physiol., 265:783-793.
5.Wakasaki H, Koya D, Schoen FJ, Jirousek MR, Ways DK, Hoit BD, Walsh RA, King GL (1997). Targeted overexpression of protein kinase C isoform in myocardium causes cardiomyopathy. PNAS., 94(17):9320-9325.
Pituitary Adenylate Cyclase Activating Polypeptides (PACAP) and Fragments
Definition
Pituitary Adenylate Cyclase Activating Polypeptides (PACAP, ADCYAP1: adenylate cyclase-activating polypeptide 1), is a neuropeptide in pancreatic islets, where it has been suggested as a parasympathetic and sensory neurotransmitter.
Discovery
In 1989, Arimura et al., isolated novel PACAP, hypophysiotropic neuropeptides, the group of Arimura has screened fractions from an extract of 4300 ovine hypothalamus by monitoring their stimulatory effect on adenylyl cyclase activity in cultured rat anterior pituitary cells. Using this approach, they have isolated in pure form a peptide, found to markedly increase cAMP formation, that they termed pituitary adenylate cyclase-activating polypeptide 1.
PACAP Fragments
The two forms of pituitary adenylate cyclase-activating Polypeptide are PACAP-27 and PACAP-38. PACAP38 (4.5 kDa), but was later found to also exist in a COOH-terminally truncated 27–amino acid long-form equivalent to PACAP38 (1–27) and thus called PACAP27 (3.0 kDa). In addition, PACAP27 is amidated at its COOH-terminal end. In all tissues examined, PACAP38 is the predominant form of PACAP. The peptide is structurally related to VIP and is therefore a member of the glucagon/VIP family of peptides comprising secretin, helodermin, helospectin, and GLP-1. In fact, PACAP27 displays 68% identity with the full length of VIP 2.
Structural Characteristics
Conformational analysis of PACAP27 by two-dimensional NMR and circular dichroism spectroscopy has shown an initial disordered N-terminus sequence of eight amino acid residues followed by a region, from amino acid residues 9 to 24, that consists of four distinct domains 3. The first domain, encompassing residues 9 to 12, forms a b-turn-like conformation whereas the three others are composed of distinct helical regions that extend from residues 12 to 14, 15 to 20, and 22 to 24, respectively. The conformation of PACAP38 mirrors that of PACAP27 in its N-terminal region whereas the C-terminal segment exhibits a short helix attached by a flexible hinge to the 1–27 region 4.
The three-dimensional structure of PACAP exhibits substantial similarities with those of other members of the VIP/glucagon family 4. In particular, both PACAP27 and VIP possess two helices separated by a disordered region, but the position of the first a-helix of PACAP27 is shifted by two residues toward the C-terminus, and the conformation of the second helix of PACAP27 is closer to an a-helix than that of VIP. These minor conformational differences between PACAP27 and VIP may contribute to the selectivity of the peptides for their receptors 3.
Mode of Action
The wide distribution of PACAP and its receptors suggests that the peptide may exert pleiotropic physiological functions. The PACAP receptor is G protein-coupled with seven transmembrane domains and also belongs to the VIP receptor family. The biological effects of PACAP are mediated through three distinct receptor subtypes which exhibit differential affinities for PACAP and VIP. The PAC1 receptor, which shows high selectivity for PACAP, is coupled to several transduction systems. In contrast, VPAC1 and VPAC2, which bind with the same affinity PACAP and VIP, are mainly coupled to the adenylyl cyclase pathway. In vivo and in vitro studies have shown that PACAP exerts multiple activities as a hormone, neurohormone, neurotransmitter or trophic factor5.
Functions
Action of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on the rat vascular system: effects on blood pressure and receptor binding: The administration of bolus doses of PACAP 38 and its 27 amino acid N-terminal fragment (PACAP 27) caused a rapid but transient dose-dependent hypotensive effect in the anaesthetized rat. The amplitude and duration of the response obtained by PACAP 38 was comparable with VIP whereas PACAP 27 was three times less potent than VIP. Furthermore, radioreceptor binding studies demonstrated that 125I-labelled PACAP 27 and 125I-labelled VIP bound to membranes prepared from blood vessels. Both PACAP 27 and VIP were capable of displacing the other from these binding sites6.
Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia: PACAP, a neuropeptide with neurotransmission modulating activity, is a promising schizophrenia candidate gene. There is evidence that genetic variants of the genes encoding PACAP and its receptor, PAC1, are associated with schizophrenia. The effects of the associated polymorphism in the PACAP gene is studied on neurobiological traits related to risk for schizophrenia. This allele of the PACAP gene, which is overrepresented in schizophrenia patients, was associated with reduced hippocampal volume and poorer memory performance. Abnormal behaviors in PACAP knockout mice, including elevated locomotor activity and deficits in prepulse inhibition of the startle response, were reversed by treatment with an atypical antipsychotic, risperidone. These convergent data suggest that alterations in PACAP signaling might contribute to the pathogenesis of schizophrenia7.
References
1.Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH (1989). Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Re. Commun., 164:567-574.
2.Miyata A, Jiang L, Dahl RR, Kitada C, Kubo K, Fujino M, Minamino N, Arimura A (1990). Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun., 170:643-648.
3.Inooka H, Endo S, Kitada C, Mizuta E and Fujino M (1992) Pituitary adenylate cyclase-activating polypeptide (PACAP) with 27 residues. Conformation determined by 1:H NMR and CD spectroscopies and distance geometry in 25% methanol solution. Int. J. Pept. Protein. Res., 40:456-464.
4.Wray V, Kokoschke C, Nokihara K and Naruse S (1993) Solution structure of pituitary adenylate cyclase-activating polypeptide by nuclear magnetic resonance spectroscopy. Biochemistry, 32:5832-5841.
5.Gonzalez BJ, Basille M, Vaudry D, Fournier A, Vaudry H (1998). Pituitary adenylate cyclase-activating polypeptide. Ann Endocrinol., 59(5):364-405.
6.KA Nandha, MA Benito-Orfila, DM Smith, MA Ghatei and SR Bloom (1991). Action of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on the rat vascular system: effects on blood pressure and receptor binding. Journal of Endocrinology, 129:69-73.
7.Hashimoto R, Hashimoto H, Shintani N, Chiba S, Hattori S, Okada T, Nakajima M, Tanaka K, Kawagishi N, Nemoto K, Mori T, Ohnishi T, Noguchi H, Hori H, Suzuki T, Iwata N, Ozaki N, Nakabayashi T, Saitoh O, Kosuga A, Tatsumi M, Kamijima K, Weinberger DR, Kunugi H, Baba A (2007). Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia. Mol Psychiatry., 12(11):1026-1032.


For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Pituitary Adenylate Cyclase Activating Polypeptides (PACAP, ADCYAP1: adenylate cyclase-activating polypeptide 1), is a neuropeptide in pancreatic islets, where it has been suggested as a parasympathetic and sensory neurotransmitter.
Discovery
In 1989, Arimura et al., isolated novel PACAP, hypophysiotropic neuropeptides, the group of Arimura has screened fractions from an extract of 4300 ovine hypothalamus by monitoring their stimulatory effect on adenylyl cyclase activity in cultured rat anterior pituitary cells. Using this approach, they have isolated in pure form a peptide, found to markedly increase cAMP formation, that they termed pituitary adenylate cyclase-activating polypeptide 1.
PACAP Fragments
The two forms of pituitary adenylate cyclase-activating Polypeptide are PACAP-27 and PACAP-38. PACAP38 (4.5 kDa), but was later found to also exist in a COOH-terminally truncated 27–amino acid long-form equivalent to PACAP38 (1–27) and thus called PACAP27 (3.0 kDa). In addition, PACAP27 is amidated at its COOH-terminal end. In all tissues examined, PACAP38 is the predominant form of PACAP. The peptide is structurally related to VIP and is therefore a member of the glucagon/VIP family of peptides comprising secretin, helodermin, helospectin, and GLP-1. In fact, PACAP27 displays 68% identity with the full length of VIP 2.
Structural Characteristics
Conformational analysis of PACAP27 by two-dimensional NMR and circular dichroism spectroscopy has shown an initial disordered N-terminus sequence of eight amino acid residues followed by a region, from amino acid residues 9 to 24, that consists of four distinct domains 3. The first domain, encompassing residues 9 to 12, forms a b-turn-like conformation whereas the three others are composed of distinct helical regions that extend from residues 12 to 14, 15 to 20, and 22 to 24, respectively. The conformation of PACAP38 mirrors that of PACAP27 in its N-terminal region whereas the C-terminal segment exhibits a short helix attached by a flexible hinge to the 1–27 region 4.
The three-dimensional structure of PACAP exhibits substantial similarities with those of other members of the VIP/glucagon family 4. In particular, both PACAP27 and VIP possess two helices separated by a disordered region, but the position of the first a-helix of PACAP27 is shifted by two residues toward the C-terminus, and the conformation of the second helix of PACAP27 is closer to an a-helix than that of VIP. These minor conformational differences between PACAP27 and VIP may contribute to the selectivity of the peptides for their receptors 3.
Mode of Action
The wide distribution of PACAP and its receptors suggests that the peptide may exert pleiotropic physiological functions. The PACAP receptor is G protein-coupled with seven transmembrane domains and also belongs to the VIP receptor family. The biological effects of PACAP are mediated through three distinct receptor subtypes which exhibit differential affinities for PACAP and VIP. The PAC1 receptor, which shows high selectivity for PACAP, is coupled to several transduction systems. In contrast, VPAC1 and VPAC2, which bind with the same affinity PACAP and VIP, are mainly coupled to the adenylyl cyclase pathway. In vivo and in vitro studies have shown that PACAP exerts multiple activities as a hormone, neurohormone, neurotransmitter or trophic factor5.
Functions
Action of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on the rat vascular system: effects on blood pressure and receptor binding: The administration of bolus doses of PACAP 38 and its 27 amino acid N-terminal fragment (PACAP 27) caused a rapid but transient dose-dependent hypotensive effect in the anaesthetized rat. The amplitude and duration of the response obtained by PACAP 38 was comparable with VIP whereas PACAP 27 was three times less potent than VIP. Furthermore, radioreceptor binding studies demonstrated that 125I-labelled PACAP 27 and 125I-labelled VIP bound to membranes prepared from blood vessels. Both PACAP 27 and VIP were capable of displacing the other from these binding sites6.
Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia: PACAP, a neuropeptide with neurotransmission modulating activity, is a promising schizophrenia candidate gene. There is evidence that genetic variants of the genes encoding PACAP and its receptor, PAC1, are associated with schizophrenia. The effects of the associated polymorphism in the PACAP gene is studied on neurobiological traits related to risk for schizophrenia. This allele of the PACAP gene, which is overrepresented in schizophrenia patients, was associated with reduced hippocampal volume and poorer memory performance. Abnormal behaviors in PACAP knockout mice, including elevated locomotor activity and deficits in prepulse inhibition of the startle response, were reversed by treatment with an atypical antipsychotic, risperidone. These convergent data suggest that alterations in PACAP signaling might contribute to the pathogenesis of schizophrenia7.
References
1.Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH (1989). Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Re. Commun., 164:567-574.
2.Miyata A, Jiang L, Dahl RR, Kitada C, Kubo K, Fujino M, Minamino N, Arimura A (1990). Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun., 170:643-648.
3.Inooka H, Endo S, Kitada C, Mizuta E and Fujino M (1992) Pituitary adenylate cyclase-activating polypeptide (PACAP) with 27 residues. Conformation determined by 1:H NMR and CD spectroscopies and distance geometry in 25% methanol solution. Int. J. Pept. Protein. Res., 40:456-464.
4.Wray V, Kokoschke C, Nokihara K and Naruse S (1993) Solution structure of pituitary adenylate cyclase-activating polypeptide by nuclear magnetic resonance spectroscopy. Biochemistry, 32:5832-5841.
5.Gonzalez BJ, Basille M, Vaudry D, Fournier A, Vaudry H (1998). Pituitary adenylate cyclase-activating polypeptide. Ann Endocrinol., 59(5):364-405.
6.KA Nandha, MA Benito-Orfila, DM Smith, MA Ghatei and SR Bloom (1991). Action of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on the rat vascular system: effects on blood pressure and receptor binding. Journal of Endocrinology, 129:69-73.
7.Hashimoto R, Hashimoto H, Shintani N, Chiba S, Hattori S, Okada T, Nakajima M, Tanaka K, Kawagishi N, Nemoto K, Mori T, Ohnishi T, Noguchi H, Hori H, Suzuki T, Iwata N, Ozaki N, Nakabayashi T, Saitoh O, Kosuga A, Tatsumi M, Kamijima K, Weinberger DR, Kunugi H, Baba A (2007). Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia. Mol Psychiatry., 12(11):1026-1032.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Peptide YY and Related Peptides
Definition
Peptide YY (PYY) is an important gut hormone synthesized and secreted by the gastrointestinal tract.
Related Peptide
PYY is a straight chain polypeptide. PYY shares structural homology with neuropeptide Y (NPY) and pancreatic polypeptide (PP) 1, and together form the Neuropeptide Y Family of Peptides, which is also called the Pancreatic Polypeptide-Fold Family of Peptides.
The PP family of peptides includes PYY and NPY, which were discovered based upon their chemical structure (possessing a carboxyl-terminal tyrosine amide) 2. PP, PYY, and NPY are all 36 amino acids in length and despite structural similarities; they are found in different locations throughout the gastrointestinal tract and nervous system and possess different biological actions. PP is expressed in endocrine cells of the gut and pancreas, PYY is located in enteroendocrine cells of the ileum and colon and nerves of the enteric nervous system, and NPY is found in the central and peripheral nervous system. This wide distribution suggests that these peptides regulate many different physiological processes.
Structural Characteristics
Human PYY consists of a linear chain of 36 amino acid residues and the complete amino acid sequence is: Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2. The differences between the structures of porcine and human PYY are at positions 3 (Ala/Ile replacement) and 18 (Ser/Asn). Synthetic human PYY prepared using a solid-phase synthetic technique was found to be structurally identical to the natural peptide3.
Mode of Action
PYY is co-secreted with glucagon-like peptide 1. Produced by the intestinal L-cells, the highest tissue concentrations of PYY are found in distal segments of the gastrointestinal tract, although it is present throughout the gut. PYY release is stimulated by intraluminal nutrients, including glucose, bile salts, lipids, short-chain fatty acids and amino acids. Regulatory peptides such as cholecystokinin (CCK), vasoactive intestinal polypeptide (VIP), gastrin and GLP-1 modulate PYY release. The proximal GI tract may also participate in the regulation of PYY release through vagal fibers. After release, dipeptidyl peptidase IV (DPP-IV; CD 26) cleaves the N-terminal tyrosine-proline residues forming PYY (3-36). PYY (1-36) represents about 60% and PYY (3-36) 40% of circulating PYY. PYY acts through Y-receptor subtypes: Y1, Y2, Y4 and Y5 in humans. PYY (1-36) shows high affinity to all four receptors while PYY (3-36) is a specific Y2 agonist. PYY inhibits many GI functions, including gastric acid secretion, gastric emptying, small bowel and colonic chloride secretion, mouth to cecum transit time, pancreatic exocrine secretion and pancreatic insulin secretion. PYY also promotes postprandial naturesis and elevates systolic and diastolic blood pressure4, 5.
Functions
PYY as a growth factor for intestinal epithelium: PYY is an abundant distal gut hormone that may play a significant role in intestinal epithelial proliferation. Gut epithelial cells express specific receptors for PYY, PYY induces proliferation in intestinal cells in vivo and in vitro, and the Y1 receptor subtype couples to mitogenic signaling pathways. In addition to proposed physiologic effects on gut mucosal maintenance, PYY proliferative effects may be hypothesized to contribute to pathophysiologic consequences of stimulated growth6.
PYY, appetite and food intake: Following food intake PYY is released into the circulation. PYY concentrations are proportional to meal energy content and peak plasma levels appear postprandially after 1 hr. PYY3-36 is a major form of PYY in both the gut mucosal endocrine cells and the circulation. Peripheral administration of PYY3-36 inhibits food intake for several hours in both rodents and man. The binding of PYY3-36 to the Y2 receptor leads to an inhibition of the NPY neurones and a possible reciprocal stimulation of the pro-opiomelanocortin neurones. Thus, PYY3-36 appears to control food intake by providing a powerful feedback on the hypothalamic circuits. The effect on food intake has been demonstrated at physiological concentrations and, therefore, PYY3-36 may be important in the everyday regulation of food intake7.
Central and peripheral regulation of gastric acid secretion by PYY: PYY released postprandially from the ileum and colon displays a potent inhibition of cephalic and gastric phases of gastric acid secretion through both central and peripheral mechanisms. To modulate vagal regulation of gastric functions, circulating PYY enters the brain through the area postrema and the nucleus of the solitary tract, where it exerts a stimulatory action through PYY-preferring Y1-like receptors, and an inhibitory action through Y2 receptors. In the gastric mucosa, PYY binds to Y1 receptors in the enterochromaffin-like cells to inhibit gastrin-stimulated histamine release and calcium signaling via a pertussis toxin-sensitive pathway8.
References
1.Tatemoto K, Carlquist M, Mutt V (1982). Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature, 296(5858):659-660.
2.Tatemoto K (1982). Neuropeptide Y: Complete amino acid sequence of the brain peptide. PNAS., 79(18):5485-5489.
3.Tatemoto K, Nakano I, Makk G, Angwin P, Mann M, Schilling J, Go VL (1988). Isolation and primary structure of human peptide YY. Biochem Biophys Res Commun., 157(2):713-717.
4.Ballantyne GH (2006). Peptide YY (1-36) and peptide YY(3-36): Part I. Distribution, release and actions. Obes Surg., 16(5):651-658.
5.Batterham RL, Bloom SR (2003). The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci., 994:162-168.
6.Mannon PJ (2002). Peptide YY as a growth factor for intestinal epithelium. Peptides, 23(2):383-388.
7.Ie Roux CW, Bloom SR (2005). Peptide YY, appetite and food intake. Proc Nutr Soc., 64(2):213-216.
8.Yang H (2002). Central and peripheral regulation of gastric acid secretion by peptide YY. Peptides, 23(2):349-358.

For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Peptide YY (PYY) is an important gut hormone synthesized and secreted by the gastrointestinal tract.
Related Peptide
PYY is a straight chain polypeptide. PYY shares structural homology with neuropeptide Y (NPY) and pancreatic polypeptide (PP) 1, and together form the Neuropeptide Y Family of Peptides, which is also called the Pancreatic Polypeptide-Fold Family of Peptides.
The PP family of peptides includes PYY and NPY, which were discovered based upon their chemical structure (possessing a carboxyl-terminal tyrosine amide) 2. PP, PYY, and NPY are all 36 amino acids in length and despite structural similarities; they are found in different locations throughout the gastrointestinal tract and nervous system and possess different biological actions. PP is expressed in endocrine cells of the gut and pancreas, PYY is located in enteroendocrine cells of the ileum and colon and nerves of the enteric nervous system, and NPY is found in the central and peripheral nervous system. This wide distribution suggests that these peptides regulate many different physiological processes.
Structural Characteristics
Human PYY consists of a linear chain of 36 amino acid residues and the complete amino acid sequence is: Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2. The differences between the structures of porcine and human PYY are at positions 3 (Ala/Ile replacement) and 18 (Ser/Asn). Synthetic human PYY prepared using a solid-phase synthetic technique was found to be structurally identical to the natural peptide3.
Mode of Action
PYY is co-secreted with glucagon-like peptide 1. Produced by the intestinal L-cells, the highest tissue concentrations of PYY are found in distal segments of the gastrointestinal tract, although it is present throughout the gut. PYY release is stimulated by intraluminal nutrients, including glucose, bile salts, lipids, short-chain fatty acids and amino acids. Regulatory peptides such as cholecystokinin (CCK), vasoactive intestinal polypeptide (VIP), gastrin and GLP-1 modulate PYY release. The proximal GI tract may also participate in the regulation of PYY release through vagal fibers. After release, dipeptidyl peptidase IV (DPP-IV; CD 26) cleaves the N-terminal tyrosine-proline residues forming PYY (3-36). PYY (1-36) represents about 60% and PYY (3-36) 40% of circulating PYY. PYY acts through Y-receptor subtypes: Y1, Y2, Y4 and Y5 in humans. PYY (1-36) shows high affinity to all four receptors while PYY (3-36) is a specific Y2 agonist. PYY inhibits many GI functions, including gastric acid secretion, gastric emptying, small bowel and colonic chloride secretion, mouth to cecum transit time, pancreatic exocrine secretion and pancreatic insulin secretion. PYY also promotes postprandial naturesis and elevates systolic and diastolic blood pressure4, 5.
Functions
PYY as a growth factor for intestinal epithelium: PYY is an abundant distal gut hormone that may play a significant role in intestinal epithelial proliferation. Gut epithelial cells express specific receptors for PYY, PYY induces proliferation in intestinal cells in vivo and in vitro, and the Y1 receptor subtype couples to mitogenic signaling pathways. In addition to proposed physiologic effects on gut mucosal maintenance, PYY proliferative effects may be hypothesized to contribute to pathophysiologic consequences of stimulated growth6.
PYY, appetite and food intake: Following food intake PYY is released into the circulation. PYY concentrations are proportional to meal energy content and peak plasma levels appear postprandially after 1 hr. PYY3-36 is a major form of PYY in both the gut mucosal endocrine cells and the circulation. Peripheral administration of PYY3-36 inhibits food intake for several hours in both rodents and man. The binding of PYY3-36 to the Y2 receptor leads to an inhibition of the NPY neurones and a possible reciprocal stimulation of the pro-opiomelanocortin neurones. Thus, PYY3-36 appears to control food intake by providing a powerful feedback on the hypothalamic circuits. The effect on food intake has been demonstrated at physiological concentrations and, therefore, PYY3-36 may be important in the everyday regulation of food intake7.
Central and peripheral regulation of gastric acid secretion by PYY: PYY released postprandially from the ileum and colon displays a potent inhibition of cephalic and gastric phases of gastric acid secretion through both central and peripheral mechanisms. To modulate vagal regulation of gastric functions, circulating PYY enters the brain through the area postrema and the nucleus of the solitary tract, where it exerts a stimulatory action through PYY-preferring Y1-like receptors, and an inhibitory action through Y2 receptors. In the gastric mucosa, PYY binds to Y1 receptors in the enterochromaffin-like cells to inhibit gastrin-stimulated histamine release and calcium signaling via a pertussis toxin-sensitive pathway8.
References
1.Tatemoto K, Carlquist M, Mutt V (1982). Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature, 296(5858):659-660.
2.Tatemoto K (1982). Neuropeptide Y: Complete amino acid sequence of the brain peptide. PNAS., 79(18):5485-5489.
3.Tatemoto K, Nakano I, Makk G, Angwin P, Mann M, Schilling J, Go VL (1988). Isolation and primary structure of human peptide YY. Biochem Biophys Res Commun., 157(2):713-717.
4.Ballantyne GH (2006). Peptide YY (1-36) and peptide YY(3-36): Part I. Distribution, release and actions. Obes Surg., 16(5):651-658.
5.Batterham RL, Bloom SR (2003). The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci., 994:162-168.
6.Mannon PJ (2002). Peptide YY as a growth factor for intestinal epithelium. Peptides, 23(2):383-388.
7.Ie Roux CW, Bloom SR (2005). Peptide YY, appetite and food intake. Proc Nutr Soc., 64(2):213-216.
8.Yang H (2002). Central and peripheral regulation of gastric acid secretion by peptide YY. Peptides, 23(2):349-358.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Parathyroid Hormones and Related Peptides
Definition
Parathyroid hormone (PTH) is secreted by the parathyroid glands as a polypeptide containing 84 amino acids.
Related Peptide
Parathyroid hormone–related peptide (PTHrP), a peptide hormone derived from normal and tumor cells that regulates bone metabolism and vascular tone, is a naturally occurring angiogenesis inhibitor.
Discovery
In 1925, Collip prepared hot hydrochloric acid extracts of the parathyroid glands, an approach which he correctly deduced was needed to free the active substance from other gland stromal components and render it soluble. The author showed that these acid extracts of the parathyroid gland would completely relieve the tetany that followed parathyroidectomy, and established the parathyroids as an endocrine gland which secreted hormone (PTH) 1.
PTHrP was discovered in association with certain types of cancer that caused elevated blood Ca2+ levels (a syndrome called humoral hypercalcemia of malignancy, or HHM) in affected patients 2.
Structural Characteristics
The teleost PTH and PTHrP amino acid sequences contain a hydrophobic presequence and a putative prosequence, indicating that these are secreted peptides. The predicted mature zPTH1 and zPTH2 are 68 and 67 amino acids long, respectively3, whereas the corresponding pufferfish pPTHA and pPTHB mature peptides are 80 and 62 amino acids, respectively4. Among the fish, human, or chicken mature PTHs, the amino acid identity is roughly 20–25%, although the sequence similarity is close to 40%. However, there is high sequence conservation of the first 34 NH2-terminal amino acid residues, and 10 residues are either identical or have undergone conservative substitutions across all PTHs4. Among the conserved residues in the fish PTHs, several are critical for receptor binding and signal transduction 3, 4.
Mode of Action
Parathyroid hormone receptors are G protein-coupled members of the secretin receptor family that interact with the NH2-terminal 34 amino acids of both PTH and PTHrP (PTH1R) or PTH only (PTH2R). The fact that the COOH-terminal regions of PTH and PTHrP have distinct functions from those mediated by the known PTH receptors suggests that other receptors may exist for these fragments 3. PTH and PTHrP bind mammalian PTH1R with indistinguishable affinity, and both ligands stimulate adenosine 3’, 5’-cyclic monophosphate (cAMP) and inositol 1,4,5-trisphosphate (IP3) accumulation with equivalent efficacy 5.
Functions
PTH-rP and osteolytic bone disease (or predominantly osteolytic bone disease): Clinical studies have shown that breast cancer cells produce increased amounts of PTH-rP when they are present in the bone microenvironment6. One of the major mechanisms by which this may occur is by tumor cell production of PTH-rP in bone. This possibly occurs as a consequence of the release of TGF- ß ?by resorbing bone, which enhances PTH-rP production by breast cancer cells. It has been found that by rendering human breast cancer cells unresponsive to TGF- ß ?by stable transfection with a dominant negative TGF- ß receptor, the tumor cells form less bone metastases and secrete reduced amounts of PTH-rP 7. Increased PTH-rP production leads to increased osteoclast formation and bone resorption, which in turn leads to increased amounts of active TGF-b, which subsequently lead to increased amounts of PTH-rP expression by the breast cancer cells.
Indirect Effects of Parathyroid Hormone on Calcium: Parathyroid hormone also affects the metabolism of inorganic phosphorus and probably of magnesium, and in this way produces secondary effects on calcium. The hormone inhibits renal tubular reabsorption of inorganic phosphorus by a direct action on the renal tubules, resulting in an increase in urinary phosphorus and a fall of serum levels. The decrease in serum levels of inorganic phosphorus tends to raise the level of calcium in the serum, by preventing precipitation of calcium phosphate in bone which occurs when the solubility product for calcium and phosphate is exceeded 8. It has been shown that in the rat, parathyroid hormone also influences transport of magnesium. Both parathyroid extract and pure bovine parathyroid hormone produce a fall in excretion of magnesium in the urine, while parathyroidectomy leads to a decrease in serum levels of magnesium 9. These workers suggest that a fall in serum level of magnesium stimulates the parathyroid glands, and the increased secretion of hormone is the cause of the hypercalcaemia which occurs in magnesium-deficient rats. Changes in concentration of magnesium may therefore upset the normal homeostatic control of calcium.
References
1.Collip JB (1925). The extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regulates the level of blood calcium. J Biol Chem., 63:395-438.
2.Moseley JM, Kubota M, Diefenbach-Jagger H, Wettenhall RE, Kemp BE, Suva LJ, Rodda CP, Ebeling PR, Hudson PJ, Zajac JD, and Martin TJ (1987). Parathyroid hormone-related protein purified from a human lung cancer cell line. PNAS., 84:5048-5052.
3.Gensure RC, Ponugoti B, Gunes Y, Papasani MR, Lanske B, Bastepe M, Rubin DA, Juppner H (2004). Identification and characterization of two parathyroid hormone-like molecules in zebrafish. Endocrinology, 145:1634-1639.
4.Canario AVM, Rotllant J, Fuentes J, Guerreiro PM, Rita Teodosio H, Power DM, Clark MS (2006). Novel bioactive parathyroid hormone and related peptides in teleost fish. FEBS Lett., 580:291–299.
5.Juppner H (1999). Receptors for parathyroid hormone and parathyroid hormone-related peptide: exploration of their biological importance. Bone, 25:87-90.
6.Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennett RC & Martin TJ (1991). Localization of parathyroid hormone-related protein in breast cancer metastases - increased incidence in bone compared with other sites. Can Res., 51:3059-3061.
7.Yin JJ, Chirgwin JM, Taylor SD, Dallas M, Massague J, Mundy GR & Guise TA (1996). Dominant negative blockade of the transforming growth factor b (TGFb) type II receptordecreases breast cancer-mediated osteolysis. Journal of Bone and Mineral Researc, 11:180.
8.Harrison MT (1964). Interrelationships of vitamin D and parathyroid hormone in calcium homeostasis. Postgrad. Med. J., 40:497-505.
9.Boss M (1963). Parathyroid Hormone and Magnesium Homceo- stasis. Nature, 198:1058.


For more detail regarding Peptide please visit here : Custom Peptide Synthesis
Parathyroid hormone (PTH) is secreted by the parathyroid glands as a polypeptide containing 84 amino acids.
Related Peptide
Parathyroid hormone–related peptide (PTHrP), a peptide hormone derived from normal and tumor cells that regulates bone metabolism and vascular tone, is a naturally occurring angiogenesis inhibitor.
Discovery
In 1925, Collip prepared hot hydrochloric acid extracts of the parathyroid glands, an approach which he correctly deduced was needed to free the active substance from other gland stromal components and render it soluble. The author showed that these acid extracts of the parathyroid gland would completely relieve the tetany that followed parathyroidectomy, and established the parathyroids as an endocrine gland which secreted hormone (PTH) 1.
PTHrP was discovered in association with certain types of cancer that caused elevated blood Ca2+ levels (a syndrome called humoral hypercalcemia of malignancy, or HHM) in affected patients 2.
Structural Characteristics
The teleost PTH and PTHrP amino acid sequences contain a hydrophobic presequence and a putative prosequence, indicating that these are secreted peptides. The predicted mature zPTH1 and zPTH2 are 68 and 67 amino acids long, respectively3, whereas the corresponding pufferfish pPTHA and pPTHB mature peptides are 80 and 62 amino acids, respectively4. Among the fish, human, or chicken mature PTHs, the amino acid identity is roughly 20–25%, although the sequence similarity is close to 40%. However, there is high sequence conservation of the first 34 NH2-terminal amino acid residues, and 10 residues are either identical or have undergone conservative substitutions across all PTHs4. Among the conserved residues in the fish PTHs, several are critical for receptor binding and signal transduction 3, 4.
Mode of Action
Parathyroid hormone receptors are G protein-coupled members of the secretin receptor family that interact with the NH2-terminal 34 amino acids of both PTH and PTHrP (PTH1R) or PTH only (PTH2R). The fact that the COOH-terminal regions of PTH and PTHrP have distinct functions from those mediated by the known PTH receptors suggests that other receptors may exist for these fragments 3. PTH and PTHrP bind mammalian PTH1R with indistinguishable affinity, and both ligands stimulate adenosine 3’, 5’-cyclic monophosphate (cAMP) and inositol 1,4,5-trisphosphate (IP3) accumulation with equivalent efficacy 5.
Functions
PTH-rP and osteolytic bone disease (or predominantly osteolytic bone disease): Clinical studies have shown that breast cancer cells produce increased amounts of PTH-rP when they are present in the bone microenvironment6. One of the major mechanisms by which this may occur is by tumor cell production of PTH-rP in bone. This possibly occurs as a consequence of the release of TGF- ß ?by resorbing bone, which enhances PTH-rP production by breast cancer cells. It has been found that by rendering human breast cancer cells unresponsive to TGF- ß ?by stable transfection with a dominant negative TGF- ß receptor, the tumor cells form less bone metastases and secrete reduced amounts of PTH-rP 7. Increased PTH-rP production leads to increased osteoclast formation and bone resorption, which in turn leads to increased amounts of active TGF-b, which subsequently lead to increased amounts of PTH-rP expression by the breast cancer cells.
Indirect Effects of Parathyroid Hormone on Calcium: Parathyroid hormone also affects the metabolism of inorganic phosphorus and probably of magnesium, and in this way produces secondary effects on calcium. The hormone inhibits renal tubular reabsorption of inorganic phosphorus by a direct action on the renal tubules, resulting in an increase in urinary phosphorus and a fall of serum levels. The decrease in serum levels of inorganic phosphorus tends to raise the level of calcium in the serum, by preventing precipitation of calcium phosphate in bone which occurs when the solubility product for calcium and phosphate is exceeded 8. It has been shown that in the rat, parathyroid hormone also influences transport of magnesium. Both parathyroid extract and pure bovine parathyroid hormone produce a fall in excretion of magnesium in the urine, while parathyroidectomy leads to a decrease in serum levels of magnesium 9. These workers suggest that a fall in serum level of magnesium stimulates the parathyroid glands, and the increased secretion of hormone is the cause of the hypercalcaemia which occurs in magnesium-deficient rats. Changes in concentration of magnesium may therefore upset the normal homeostatic control of calcium.
References
1.Collip JB (1925). The extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regulates the level of blood calcium. J Biol Chem., 63:395-438.
2.Moseley JM, Kubota M, Diefenbach-Jagger H, Wettenhall RE, Kemp BE, Suva LJ, Rodda CP, Ebeling PR, Hudson PJ, Zajac JD, and Martin TJ (1987). Parathyroid hormone-related protein purified from a human lung cancer cell line. PNAS., 84:5048-5052.
3.Gensure RC, Ponugoti B, Gunes Y, Papasani MR, Lanske B, Bastepe M, Rubin DA, Juppner H (2004). Identification and characterization of two parathyroid hormone-like molecules in zebrafish. Endocrinology, 145:1634-1639.
4.Canario AVM, Rotllant J, Fuentes J, Guerreiro PM, Rita Teodosio H, Power DM, Clark MS (2006). Novel bioactive parathyroid hormone and related peptides in teleost fish. FEBS Lett., 580:291–299.
5.Juppner H (1999). Receptors for parathyroid hormone and parathyroid hormone-related peptide: exploration of their biological importance. Bone, 25:87-90.
6.Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennett RC & Martin TJ (1991). Localization of parathyroid hormone-related protein in breast cancer metastases - increased incidence in bone compared with other sites. Can Res., 51:3059-3061.
7.Yin JJ, Chirgwin JM, Taylor SD, Dallas M, Massague J, Mundy GR & Guise TA (1996). Dominant negative blockade of the transforming growth factor b (TGFb) type II receptordecreases breast cancer-mediated osteolysis. Journal of Bone and Mineral Researc, 11:180.
8.Harrison MT (1964). Interrelationships of vitamin D and parathyroid hormone in calcium homeostasis. Postgrad. Med. J., 40:497-505.
9.Boss M (1963). Parathyroid Hormone and Magnesium Homceo- stasis. Nature, 198:1058.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
P60c-src
Definition
1.Rous P (1911). A Sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med., 13 (4):397-411.
2.Brickell PM (1992). The p60c-src family of protein-tyrosine kinases: structure, regulation, and function. Crit. Rev. Oncog.,
3(4):401-446. 3.Kefalas P, Brown TR, Brickell PM (1995). Signalling by the p60c-src Family of Protein-Tyrosine Kinases. Int J Biochem Cell Biol., 27(6):551-563.
4.Levy JB, Iba H, Hanafusa H (1986). Activation of the transforming potential of p60c-src by a single amino acid change. PNAS., 83(12):4228-4232.
5.Kefalas P, Brown TR, Brickell PM (1995). Signalling by the p60c-src family of protein-tyrosine kinases. Int J Biochem Cell Biol., 27(6):551-563.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis
The cellular proto-oncogene p60c-src (src) is a cytosolic nonreceptor tyrosine kinase.
Discovery In 1911, Peyton Rous reported that a fibrosarcoma could be transmitted between chickens in a cell-free extract of the tumor1. The transmissible agent, Rous sarcoma virus (RSV), transforms cells by virtue of the presence within its genome of a viral oncogene, v-src, which is derived from a normal cellular gene that has been picked up, or transduced, by the virus. This cellular proto-oncogene, c-src, encodes a protein, p60c-src, which has the ability to phosphorylate proteins on tyrosine residues. Studies of RSV were thus directly responsible for the discovery of cellular proto-oncogenes and of protein-tyrosine kinases, discoveries which have been fundamental in shaping ideas about cellular growth control2.
Structural Characteristics The c-src gene family has nine known members (blk, c-fgr, fyn, hck, lck, lyn, c-src, c-yes and yrk), each encoding a cytoplasmic protein-tyrosine kinase (PTK) believed to be involved in signal transduction. The c-src PTKs contain three domains (SH1, SH2 and SH3) that are found in many other signalling proteins. The SH1 domain has PTK activity, whilst the SH2 and SH3 domains are involved in mediating protein-protein interactions by binding to phosphotyrosine-containing and proline-rich motifs, respectively3.
Mode of Action A study showed that, when compared to the DNA sequence of the parental c-src viruses, the two transforming mutant src viruses contain single point mutations that result in single amino acid changes in the src gene products (p60 proteins). Both amino acid changes reside in the tyrosine kinase domain of the protein. The mutation detected in one virus involves replacement of the normal Glu-378 in p60c-src by Gly, whereas the p60 of the other transforming virus has Phe instead of the normal Ile-441. This indicates that when p60c-src is expressed at elevated levels in a retroviral context, a single amino acid change in its primary sequence can activate the kinase activity of this protein and cause cellular transformation4.
Functions p60c-src function in a broad range of biological situations, regulating the behaviour of terminally differentiated, post-mitotic cell types. Targeted disruption of members of the c-src family in transgenic mice has confirmed important roles in T-lymphocyte maturation and activation. p60c-src also plays an important role in bone maintenance, learning, memory and signal transduction which mediate cell growth, differentiation, transformation and tissue remodeling in various organs5.
References:1.Rous P (1911). A Sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med., 13 (4):397-411.
2.Brickell PM (1992). The p60c-src family of protein-tyrosine kinases: structure, regulation, and function. Crit. Rev. Oncog.,
3(4):401-446. 3.Kefalas P, Brown TR, Brickell PM (1995). Signalling by the p60c-src Family of Protein-Tyrosine Kinases. Int J Biochem Cell Biol., 27(6):551-563.
4.Levy JB, Iba H, Hanafusa H (1986). Activation of the transforming potential of p60c-src by a single amino acid change. PNAS., 83(12):4228-4232.
5.Kefalas P, Brown TR, Brickell PM (1995). Signalling by the p60c-src family of protein-tyrosine kinases. Int J Biochem Cell Biol., 27(6):551-563.
Subscribe to:
Posts (Atom)